Abstract 100P
Background
Colorectal cancer ranks as the third most prevalent cancer globally and stands as the second primary contributor to cancer-related mortality. Utilization of a phenomic data approach allows researchers to reveal the mechanisms and molecular pathogenesis of colorectal cancer. We aimed to investigate the correlation between the phenomic features and colorectal cancer in a large cohort study.
Methods
We included 502369 subjects aged 37-73 years in the UK Biobank recruited since 2006. In total, 59 parameters exploring socio-demographic factors, blood chemistry, anthropometric measurements and lifestyle factors of participants collected at baseline assessment were analysed. Univariate and multivariate logistic regression were conducted to examine the associations of these parameters with colorectal cancer risk, based on the odds ratio (OR) and 95% confidence intervals (CI).
Results
The analysis included a total of 438625 participants, of which 5436 (1.2%) were incident colorectal cancer cases and 433189 were healthy controls. A marker, cystatin C was associated with colorectal cancer (adjusted OR 2.11; 95% CI 1.92-2.32). Compared to Asians, Whites ethnicity had higher risk of developing colorectal cancers (adjusted OR 2.54; 95% CI 1.93-3.34). In addition to colorectal cancer, Cystatin C and ethnicity are consistently associated with total gastrointestinal cancers. Cystatin C and ethnicity appear to be important features in GI cancers, suggesting some overlap in the molecular pathogenesis of GI cancers.
Conclusions
Cystatin C and ethnicity emerged as a consistent biomarker associated with different types of gastrointestinal cancers, including colorectal cancer. In order to provide more in-depth understanding of how these factors were associated with gastrointestinal cancers and shed light on the molecular pathogenesis of gastrointestinal cancers, future research will employ a multi-modal approach exploring the genomics and proteomics of the UK Biobank cohort.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract